VYNDAQEL DIN 02495732
Health Canada record
| Active ingredient(s) | TAFAMIDIS MEGLUMINE 20 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N07XX08 TAFAMIDIS |
| Original market date | 07-Apr-2020 |
| Current status date | 07-Apr-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23118 | 2020-01-20 | New Drug Submission (NDS) |
International API supply for TAFAMIDIS MEGLUMINE
13 active FDA Drug Master Files.
Request a quote for VYNDAQEL